GRAIL, Inc. (GRAL)
- Previous Close
42.89 - Open
37.40 - Bid 32.62 x 200
- Ask 33.31 x 100
- Day's Range
32.51 - 40.25 - 52 Week Range
12.33 - 63.99 - Volume
4,125,251 - Avg. Volume
1,458,638 - Market Cap (intraday)
1.162B - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-63.54 - Earnings Date Aug 11, 2025 - Aug 15, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
31.50
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
grail.com1,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Industry
Recent News: GRAL
View More
Performance Overview: GRAL
Trailing total returns as of 5/14/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: GRAL
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: GRAL
View MoreValuation Measures
Market Cap
1.51B
Enterprise Value
818.55M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
10.89
Price/Book (mrq)
0.60
Enterprise Value/Revenue
6.52
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-11.98%
Return on Equity (ttm)
-62.22%
Revenue (ttm)
130.71M
Net Income Avi to Common (ttm)
-1.91B
Diluted EPS (ttm)
-63.54
Balance Sheet and Cash Flow
Total Cash (mrq)
674.58M
Total Debt/Equity (mrq)
2.67%
Levered Free Cash Flow (ttm)
--